Personalis, Inc. $PSNL Shares Bought by Aberdeen Group plc

Aberdeen Group plc increased its holdings in shares of Personalis, Inc. (NASDAQ:PSNL) by 36.1% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 3,249,895 shares of the company’s stock after purchasing an additional 861,948 shares during the quarter. Aberdeen Group plc’s holdings in Personalis were worth $25,869,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in PSNL. Kennedy Capital Management LLC grew its holdings in Personalis by 196.2% in the 3rd quarter. Kennedy Capital Management LLC now owns 1,935,078 shares of the company’s stock valued at $12,617,000 after buying an additional 1,281,695 shares during the period. ARK Investment Management LLC grew its holdings in Personalis by 11.3% in the third quarter. ARK Investment Management LLC now owns 7,910,191 shares of the company’s stock valued at $51,574,000 after purchasing an additional 802,268 shares during the period. Blue Water Life Science Advisors LP grew its holdings in Personalis by 42.6% in the second quarter. Blue Water Life Science Advisors LP now owns 1,676,300 shares of the company’s stock valued at $10,997,000 after purchasing an additional 500,900 shares during the period. Ameriprise Financial Inc. increased its position in Personalis by 1,172.0% during the second quarter. Ameriprise Financial Inc. now owns 329,865 shares of the company’s stock worth $2,164,000 after purchasing an additional 303,933 shares during the last quarter. Finally, Oracle Investment Management Inc. acquired a new position in Personalis during the third quarter worth approximately $1,496,000. 61.91% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have weighed in on PSNL shares. Wall Street Zen upgraded shares of Personalis from a “sell” rating to a “hold” rating in a report on Sunday, March 8th. Guggenheim upped their price objective on Personalis from $12.00 to $13.00 and gave the stock a “buy” rating in a report on Monday, January 26th. BTIG Research increased their target price on Personalis from $12.00 to $13.00 and gave the stock a “buy” rating in a research report on Wednesday, February 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Personalis in a report on Thursday, January 22nd. Finally, Needham & Company LLC boosted their price target on Personalis from $10.00 to $12.00 and gave the company a “buy” rating in a research report on Friday, February 27th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Personalis has a consensus rating of “Moderate Buy” and a consensus target price of $11.50.

Personalis Price Performance

Personalis stock opened at $6.58 on Monday. The firm has a fifty day moving average of $8.11 and a 200-day moving average of $8.41. Personalis, Inc. has a 52-week low of $2.83 and a 52-week high of $11.50. The firm has a market capitalization of $688.47 million, a P/E ratio of -7.23 and a beta of 2.20.

Personalis (NASDAQ:PSNL) last posted its earnings results on Thursday, February 26th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.05. Personalis had a negative net margin of 116.69% and a negative return on equity of 39.13%. The business had revenue of $17.35 million for the quarter, compared to analyst estimates of $17.12 million. On average, research analysts expect that Personalis, Inc. will post -1.4 EPS for the current fiscal year.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.